Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine

Alopecia areata (AA) is a chronic autoimmune disorder characterized by non-scarring hair loss. Immune dysregulation, particularly involving B and T cells (CD8+ cytotoxic, CD4+ helper, and regulatory T cells), plays a central role in AA pathogenesis. Emerging immune-modulating biologics offer more targeted alternatives to traditional treatments, such as JAK inhibitors or corticosteroids. A review of clinical trials, case series, and case reports sourced from PubMed was conducted to evaluate the efficacy of immune cell-modulating biologics in treating AA. Nivolumab and rituximab yielded complete remission of AA in case reports. Alefacept showed modest efficacy, with only two patients achieving ≥50% SALT improvement in a clinical trial, while partial to complete regrowth was observed in all patients in the case reports. Aldesleukin led to a 50% SALT reduction in 14.3% of patients in a randomized trial and partial hair regrowth in 80% in a pilot study. Abatacept and efalizumab had mixed results, with 3-91% regrowth in 70% of patients for abatacept, and no significant benefit in a trial, but 70-100% regrowth in case reports for efalizumab. Further investigation into immunological endotypes and potential combination strategies is critical to developing tailored therapies that optimize treatment outcomes for AA patients.